Biblio
C
Eskelund CWinther, Husby S, Favero F, Klausen TWirenfeldt, Rodriguez-Gonzalez FGerman, Kolstad A, Pedersen LBredo, Räty RKatariina, Geisler CH, Jerkeman M, et al. Clonal hematopoiesis evolves from pre-treatment clones and stabilizes after end of chemotherapy in patients with MCL. Blood. 2020.
E
Dahl M, Husby S, Eskelund CW, Besenbacher S, Fjelstrup S, Côme C, Ek S, Kolstad A, Räty R, Jerkeman M, et al. Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials. Leukemia. 2021.
I
Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomis. Lancet. 2024.
N
Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R, Pedersen LBredo, Loft A, Bogsrud TVelde, Kimby E, et al. Nordic MCL-3 study: BEAM/C conditioning intensified with 90Y-Ibritumomab-Tiuxetan in responding non-CR patients followed by autologous transplant in mantle cell lymphoma. Blood. 2014.